Literature DB >> 18500693

Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results.

Martijn P M Q van Gils1, Daphne Hessels, Christina A Hulsbergen-van de Kaa, J Alfred Witjes, Cornelius F J Jansen, Peter F A Mulders, Harry G Rittenhouse, Jack A Schalken.   

Abstract

BACKGROUND: Due to the drawbacks of serum prostate-specific antigen, there is an ongoing search for new diagnostic and prognostic prostate cancer (PCa) markers. PCA3 has proven to be of value in the diagnosis of PCa. However, so far few attempts have been made to investigate the prognostic value of PCA3. Our objective was to further investigate the prognostic value of PCA3.
METHODS: In this study we correlated the PCA3 score in urinary sediments after digital rectal examination in 62 men with the classical prognostic parameters assessed in radical prostatectomy specimens (i.e. Gleason score, pathological tumor stage and total tumor volume) and moreover, with the expression of three immunohistochemical markers for PCa biological aggressiveness (i.e. E-cadherin, alpha-catenin and EZH2). The results from this study serve as a reflection on and a valuable adjunct to recently published results.
RESULTS: We did not find a significant correlation of the PCA3 score with the classical prognostic parameters assessed in radical prostatectomy specimens or the expression of the immunohistochemical markers for PCa biological aggressiveness. However, we did observe a trend for a higher PCA3 score in significant PCa versus insignificant PCa, aberrant E-cadherin staining versus normal E-cadherin staining and increased EZH2 staining versus normal EZH2 staining.
CONCLUSIONS: In this study we could not prove the prognostic value of PCA3. Further research with large numbers of men and adequate follow-up is needed to provide a definitive answer to the question if PCA3 is not only a diagnostic but also a prognostic PCa marker. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500693     DOI: 10.1002/pros.20781

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.

Authors:  Tian-Bao Huang; Chuan-Peng Dong; Guang-Chen Zhou; Sheng-Ming Lu; Yang Luan; Xiao Gu; Lei Liu; Xue-Fei Ding
Journal:  Int Urol Nephrol       Date:  2017-02-10       Impact factor: 2.370

2.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

Authors:  Said Rahim; Aykut Uren
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

Review 3.  The role of prostate cancer biomarkers in undiagnosed men.

Authors:  Hasan Dani; Stacy Loeb
Journal:  Curr Opin Urol       Date:  2017-05       Impact factor: 2.309

4.  Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer.

Authors:  John V Hegde; Darlene Veruttipong; Jonathan W Said; Robert E Reiter; Michael L Steinberg; Christopher R King; Amar U Kishan
Journal:  Urology       Date:  2017-05-25       Impact factor: 2.649

Review 5.  Urinary biomarkers for prostate cancer: a review.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Asian J Androl       Date:  2013-03-25       Impact factor: 3.285

6.  Prostate cancer markers: An update.

Authors:  Srinivas Pentyala; Terry Whyard; Sahana Pentyala; John Muller; John Pfail; Sunjit Parmar; Carlos G Helguero; Sardar Khan
Journal:  Biomed Rep       Date:  2016-01-29

Review 7.  The use of PCA3 in the diagnosis of prostate cancer.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

Review 8.  PCA3 in the detection and management of early prostate cancer.

Authors:  Xavier Filella; Laura Foj; Montserrat Milà; Josep M Augé; Rafael Molina; Wladimiro Jiménez
Journal:  Tumour Biol       Date:  2013-03-16

Review 9.  Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.

Authors:  Stacy Loeb; Hasan Dani
Journal:  Urol Clin North Am       Date:  2017-11       Impact factor: 2.241

10.  PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols.

Authors:  Michael A Liss; Rosanne Santos; Kathryn Osann; Alice Lau; Thomas E Ahlering; David K Ornstein
Journal:  World J Urol       Date:  2010-12-09       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.